RT Journal Article
SR Electronic
T1 IMPACT OF GLUCOCORTICOID TREATMENT IN SARS-COV-2 INFECTION MORTALITY: A RETROSPECTIVE CONTROLLED COHORT STUDY
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.05.22.20110544
DO 10.1101/2020.05.22.20110544
A1 Fernández Cruz, Ana
A1 Ruiz-Antorán, Belén
A1 Gómez, Ana Muñoz
A1 Sancho López, Aránzazu
A1 Sánchez, Patricia Mills
A1 Soto, Gustavo Adolfo Centeno
A1 Alonso, Silvia Blanco
A1 Garachana, Laura Javaloyes
A1 Gómez, Amy Galán
A1 Alijo, Ángela Valencia
A1 Irusta, Javier Gómez
A1 Payares-Herrera, Concepción
A1 Torre, Ignacio Morrás
A1 Chica, Enrique Sánchez
A1 de Cepeda, Laura Delgado Téllez
A1 Díaz, Alejandro Callejas
A1 Ramos Martínez, Antonio
A1 Rubio, Elena Múñez
A1 Avendaño-Solá, Cristina
A1 ,
YR 2020
UL http://medrxiv.org/content/early/2020/05/26/2020.05.22.20110544.abstract
AB Objective We aim to determine the impact of steroid use in COVID-19 pneumonia in-hospital mortality.Design We performed a single-centre retrospective cohort study.Setting A University hospital in Madrid, Spain, during March 2020.Participants Patients admitted with SARS-CoV-2 pneumonia.Exposures Patients treated with steroids were compared to patients not treated with steroids. A propensity-score for steroid treatment was developed. Different steroid regimens were also compared, and adjusted with a second propensity score.Main Outcomes and Measures To determine the role of steroids in in-hospital mortality, univariable and multivariable analyses were performed, and adjusted including the propensity score as a covariate. Survival times were compared using a log-rank test.Results During the study period, 463 out of 848 hospitalized patients with COVID19 pneumonia fulfilled inclusion criteria. Among them, 396 (46.7%) consecutive patients were treated with steroids and 67 patients were assigned to the control cohort. Global mortality was 15.1%. Median time to steroid treatment from symptom onset was 10 days (IQR 8 to13). In-hospital mortality was lower in patients treated with steroids than in controls (13.9% [55/396] versus 23.9% [16/67], OR 0.51 [0.27 to 0.96], p= 0.044). Steroid treatment reduced mortality by 41.8% relative to no steroid treatment (RRR 0,42 [0.048 to 0.65). Initial treatment with 1 mg/kg/day of methylprednisolone (or equivalent) versus steroid pulses was not associated with in-hospital mortality (13.5% [42/310] versus 15.1% [13/86], OR 0.880 [0.449-1.726], p=0.710).Conclusions Our results show that survival of patients with SARS-CoV2 pneumonia is higher in patients treated with glucocorticoids than in those not treated. In-hospital mortality was not different between initial regimens of 1 mg/kg/day of methylprednisolone or equivalent and glucocorticoid pulses. These results support the use of glucocorticoids in SARS-CoV2 infection.Summary We investigated in-hospital mortality of patients with SARS-CoV-2 pneumonia in a large series of patients treated with steroids compared to controls, and adjusted using a propensity score. Our results show a beneficial impact of steroid treatment in SARS-CoV-2 pneumonia.Competing Interest StatementThe authors have declared no competing interest.Clinical Protocols http://www.encepp.eu/encepp/studySearch.htm Funding StatementThe study did not receive any funding.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Institutional Review Board (CEIm) at Hospital Universitario Puerta de Hierro Majadahonda (BRA COR 2020 03), and a waiver for the informed consent was granted. The study complied with the provisions in EU and Spanish legislation on data protection and the Declaration of Helsinki 2013.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAfter publication, the data will be made available to others on reasonable requests to the corresponding authors. A proposal with a detailed description of study objectives and statistical analysis plan will be needed for evaluation of the reasonability of requests. Additional materials might also be required during the process of evaluation. De-identified participant data will be provided after approval from the principal researchers of the Hospital Puerta de Hierro-Majadahonda. ABBREVIATIONSSARS-CoVsevere acute respiratory syndrome coronavirusCOVID-19coronavirus disease 2019Steroidsglucocorticoids or corticoidsOROdds ratioMERS-CoVMiddle east respiratory syndrome coronavirusPaO2/FiO2arterial oxygen tension/inspiratory oxygen fractionCTcomputed tomographyARDSacute respiratory distress syndromeCRPC-reactive proteinPEEPpositive end expiratory pressureSDstandard deviationCIconfidence intervalPSMpropensity-score matchingRRRrelative risk reductionNNTnumber necessary to treatHRhazard ratioIQRinterquartile rangeCOPDchronic obstructive pulmonary diseaseLDHLactate dehydrogenaseSpO2plasma oxygen saturationICUIntensive care Unit